MacroGenics changes its tune on Linnet
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
AACR 2026 – Qilu challenges Torl in Claudin6
The company’s conjugate QLS5132 has produced intriguing, but early results.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
ESMO 2025 preview – Astra joins the folate fray
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
